FX-322 in Sensorineural Hearing Loss

Related Clinical Trial
The Performance of a Robot-assisted Minimally Invasive Direct Cochlear Access for Cochlear Implantation Auditory Performances With Different Stimulation Depths in Cochlear Implanted Subjects Using a Fine Structure Strategy Feasibility of the Mi2000 Totally Implantable Cochlear Implant in Severely to Profoundly Deaf Adults. Hearing Aid Noise Reduction in Pediatric Users Pilot Study (Oticon Pilot Study) Phase I/IIa Study Evaluating Safety and Efficacy of an Intratympanic Dose of PIPE-505 in Subjects With Hearing Loss Dexamethasone-Eluting Cochlear Implant Electrode Artificial Intelligence in Diagnosis of DFNA9 Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC Cochlear Implant and Vestibular Function. Quality Control of CE-Certified Phonak Hearing Aids – 2018_42 Quality Control of CE-Certified Phonak Hearing Aids – 2018_28 Enlarged Vestibular Aqueduct Registry Evaluation of the High Frequency Digit Triplet Test in Cystic Fibrosis Effectiveness of P02 Digital Hearing Aids ABR Characteristics and Salivary Cortisone Concentration in Noise-exposed Workers Clinical Investigation of New CI Delivery Models in an Adult Nucleus CI Population Genetic Analysis of Hereditary Disorders of Hearing and Balance Compassionate Use Arm – ABI541 ABI for 10 NF2 Patients Evaluation of a Binaural Beamformer (StereoZoom) in a Virtual Acoustic Environment and in Real Life Evaluation of N6 Sound Processor in Group of Freedom Users Robotic Assisted Cochlear Implantation Feasibility Study Auditory Nerve Test System During Vestibular Schwannoma Resection Cochlear Electrical Impedance and the Effect of Topical Dexamethasone on Cochlear Implant Surgery Comparison Between Neuro 1 and Neuro 2 Cochlear Implant Speech Processors Listening Effort in Cochlear Implant Users Quality Control of CE-Certified Phonak Hearing Aids – 2019_19 Esteem Totally Implantable Hearing System A Clinical Trial of Anakinra for Steroid-Resistant Autoimmune Inner Ear Disease Study of Quality Perception on Music in New Cochlear Implanted Subjects Using or Not a Fine Structure Strategy An Evidence Based Delivery Model of Care for Newly Implanted Adult CI Recipients Study of Auditory Performance on Prosodic Tests in Cochlear Implanted Subjects Using a Fine Structure Strategy CI532 – Early Experience Study Clinical Applications of Round Window Imaging Anatomy in Cochlear Implant Surgery Single-sided Deafness and Cochlear Implants Cochlear Implantation Among Adults and Older Children With Unilateral or Asymmetric Hearing Loss Clinal Evaluation of Navigation Based Functional Ear Surgery Using Image Guided and Robotically Assisted Techniques OTO-413 in Subjects With Speech-in-Noise Hearing Impairment The Efficacy of a Minimally Invasive Direct Cochlear Access Via the HEARO Procedure Clinical Evaluation of a Cochlear Implant System Objective Measures in Cochlear Implant Evaluation of a Binaural Spatialization Method for Hearing Aids Esteem New Subject Enrollment Post Approval Study Safety of Autologous Stem Cell Infusion for Children With Acquired Hearing Loss Investigation of Anatomical Correlates of Speech Discrimination Efficacy of Digital Noise Reduction Strategies: A Hearing Aid Trial Evaluation of Revised Indicatons (ERID) for Cochlear Implant Candidacy for the Adult CMS Population Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts Balance in Children With Cochlear Implants Congenital Cytomegalovirus: Efficacy of Antiviral Treatment Nucleus Freedom Cochlear Implant System Pediatric Post-approval Study Evaluation of the Nucleus Hybrid™ L24 Cochlear Implant System Radiological Classification of the Facial Nerve Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Randomized Controlled Trial The Effect of Sound Stimulation on Hearing Ability The Effect of Sound Stimulation on Pure-tone Hearing Threshold Efficacy of SENS 401 in Subjects With Severe or Profound Sudden Sensorineural Hearing Loss The SeaSHeL National Prospective Cohort Study Non-linear Frequency Compared to Conventional Processing in Patients With and Without Cochlear Dead Regions. Study of Low Level Laser Therapy and Word Recognition in Hearing Impaired Individuals Electrode Placement and Audiologic Outcomes With the Advanced Bionics HiFocus L23 Electrode Video HIT in Sudden Sensorineural Hearing Loss Determine the Incidence of Long QT Amongst a Large Cohort of Subjects Diagnosed With Unilateral or Bilateral Sensorineural Hearing Loss. FX-322 in Sensorineural Hearing Loss Autologous Bone Marrow Harvest and Transplant for Sensorineural Hearing Loss FX-322 in Adults With Stable Sensorineural Hearing Loss

Brief Title

FX-322 in Sensorineural Hearing Loss

Official Title

A Phase 1/2 Randomized, Double-blind, Placebo-controlled, Single-dose Study of FX-322 Administered by Intratympanic Injection in Adults With Stable Sensorineural Hearing Loss

Brief Summary

      This is a phase 1/2 single dose study of FX-322 compared to placebo in male and female adults
      otherwise healthy with stable sensorineural hearing loss.
    

Detailed Description

      Sensorineural hearing loss (SNHL) accounts for about 90% of all cases of hearing loss. The
      study will assess the safety of FX-322 given as a single intratympanic injection in subjects
      with a medical history of sensorineural hearing loss that is associated with noise exposure
      or sudden hearing loss. Safety will be evaluated both systemically (lab and clinical
      monitoring) and locally (otoscopy and audiometry) in 24 subjects, and a blood PK profile of
      FX-322 will also be determined.
    

Study Phase

Phase 1/Phase 2

Study Type

Interventional


Primary Outcome

Number of participants with treatment-related adverse events assessed by CTCAE v5.0

Secondary Outcome

 Time-concentration profile of FX-322 in plasma

Condition

Sensorineural Hearing Loss

Intervention

FX-322

Study Arms / Comparison Groups

 FX-322 Low Dose
Description:  Single intratympanic injection of a hydrogel formulation

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

23

Start Date

July 3, 2018

Completion Date

April 1, 2019

Primary Completion Date

December 31, 2018

Eligibility Criteria

        Inclusion Criteria:

          1. Adult aged 18-65 years.

          2. Established diagnosis of stable sensorineural hearing loss (no changes of 10 dB or
             more at any frequency) by standard audiometric measures for >6 months.

          3. Documented medical history consistent with hearing loss being caused by noise exposure
             or sudden sensorineural hearing loss (documented audiogram at least 6 months prior to
             screening required).

          4. Female subjects must be of non-childbearing potential or will need to utilize two
             methods of highly effective contraception during the study participation (e.g.
             hormonal contraception or an intrauterine device and condoms) or remain abstinent.
             Male subjects should use condoms with spermicide during the course of the study or
             remain abstinent. Subjects should not donate sperm or ova during the study period.

        Exclusion Criteria:

          1. Perforation of tympanic membrane or other tympanic membrane disorders that would
             interfere with the delivery and safety assessment of an intratympanic medication or
             reasonably be suspected to affect tympanic membrane healing after injection in either
             ear. This includes a current tympanostomy tubes.

          2. Any conductive hearing loss of 10 dB or more at two or more frequencies in either ear.

          3. A pure tone average of 70 dB or greater at 500Hz, 1000Hz, 2000Hz, and 4000Hz in the
             ear to be injected.

          4. Active chronic middle ear disease or a history of major middle ear surgery, as an
             adult, in the ear to be injected.

          5. Subject has had an intratympanic injection in either ear within 6 months of the
             screening visit.

          6. History of clinically significant vestibular symptoms at the discretion of the
             investigator.

          7. History of clinically significant systemic autoimmune disease (e.g. rheumatoid
             arthritis, Sjogren's syndrome, multiple sclerosis, psoriasis).

          8. History of head or neck radiation treatment or exposure.

          9. History of substance abuse within 2 years of the Screening Visit.

         10. Positive urine pregnancy test or breast-feeding.

         11. Any known factor, condition or disease that, in the view of the investigator, might
             interfere with treatment compliance, study conduct or interpretation of the results
             such as psychiatric disease or suicidal tendencies.
      

Gender

All

Ages

18 Years - 65 Years

Accepts Healthy Volunteers

No

Contacts

George Atiee, MD, , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT03616223

Organization ID

FX-322-201


Responsible Party

Sponsor

Study Sponsor

Frequency Therapeutics


Study Sponsor

George Atiee, MD, Principal Investigator, Worldwide Clinical Trials


Verification Date

September 2020